<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65592">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02059538</url>
  </required_header>
  <id_info>
    <org_study_id>P121102</org_study_id>
    <secondary_id>IDRCB2013-A00189-36</secondary_id>
    <nct_id>NCT02059538</nct_id>
  </id_info>
  <brief_title>Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases</brief_title>
  <acronym>METACARDIS</acronym>
  <official_title>Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supported by state-of-the-art systems medicine competences including integrative
      computational and functional genomics, the overarching goal of the trial is to investigate
      the impact of qualitative and quantitative changes in the gut microbiota on the pathogenesis
      of cardiometabolic diseases (CMDs) and their associated co-morbidities. A major objective
      will be to translate the clinical and fundamental based discoveries into new diagnosis and
      preventive actions paving the way to novel modes of treatment in the successive stages of
      CMD progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular diseases represent a huge medico-economic issue that is supported by public
      health policy. It is linked not only to the high prevalence of these diseases but also the
      associated cost they encounter for. Therefore, it seems rather urgent to create and validate
      tools to predict evolution of this group of disease in order to better take care of patients
      before they enter the more chronic stages which induce increased costs and socioeconomic and
      medical burdens.

      It is now well acknowledged that gut microbiota is modified in some metabolic disease such
      as type-2 diabetes but also in inflammatory diseases. However, gut microbiota is still
      insufficiently explored in cardiovascular disease, although it could represent a useful,
      non-invasive and practical tool in the daily care of patients.

      Investigators aim to deepen the knowledge and characterization of gut microbiota in patients
      going from metabolic diseases such as metabolic syndrome, obesity and type 2 diabetes (which
      are risks factors for cardiovascular diseases) to overt coronary artery diseases (from the
      first event to end stage heart failure). Investigators will use a system medicine approach
      whose aim is to integrate numerous data coming from different technologies (including
      environment, transcriptomics, metabolomics, metagenomics, lipidomics and bioinformatics).
      These integrated approaches are needed to translate basic science findings into clinical
      practice for the benefit of the patients.

      Investigators aim to uncover new microbial signatures that could help diagnose and/or
      predict both the natural evolution of cardiometabolic diseases and the response to
      treatment. Investigators aim to go forward personalized medicine.

      Patients will be approached for enrolment during their hospitalization in the 3 centers
      during the 24-month enrolment phase (WP3). Once the informed consent completed, each patient
      will be assessed for CMD phenotypes including clinical examination, environmental and food
      habit evaluation, blood urine and feces samples. In each group of patients, a sub-sample of
      30 to 50 subjects will be included in one or more advanced phenotyping items. This will
      include whole body composition by absorptiometry (DXA), abdominal visceral fat by
      tomodensitometry, Oral Glucose Tolerance Test (OGTT) (glucose, insulin, incretins),
      subcutaneous fat biopsy, cardiac echocardiography, intima media thickness, pulse wave
      velocity. For the obese patients undergoing bariatric surgery: liver and subcutaneous and
      omental adipose tissue biopsies will be obtained during surgery.

      This group of patient will be followed at 3, 6 and 12 months after their surgery and will
      have the same examination as mentioned above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Look for differences in gut microbiota signatures using metagenomic approach in the 8 different groups</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Look for differences in gut microbiota signatures using metagenomic approach in the 8 different groups (metabolic syndrome, type 2 diabetes, obesity, acute coronary event, chronic coronaropathy with or without cardiac insufficiency, cardiac insufficiency without coronaropathy and controls), in order to uncover gut derived signature associated with CMD stages</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish differences in fecal metabolomic signatures using 1H nuclear magnetic resonance (NMR) spectroscopy and Ultra-high Performance Liquid Chromatography Mass Spectrometry ((UPLC-MS) on fecal samples) in the 8 different groups (cf above mentioned)</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Establish differences in systemic and adipose tissue inflammatory patterns (using multiplex array and adipose tissue transcriptomic) in the 8 above mentioned groups</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Establish host metabolomic differences in the 8 groups in order to obtain a CMD metabolomic derived signature (using 1H nuclear magnetic resonance) spectroscopy and Ultra-high Performance Liquid Chromatography Mass Spectrometry (in serum and urine)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Establish a statistical association between host metabolomic signatures (cf above 3 in serum and urine) and the gut metagenomic signatures in the 8 groups</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Establish a diet related signature of CMD stages by looking for differences in diet in the 8 groups (using Food Frequency Questionnaire (FFQ) and three day 24h diet recall)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Establish an environment related signature of CMD stages by looking at differences in environment in the 8 groups (using data obtained from environment questionnaires)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Look for statistical association between gut derived signatures and lifestyle factors such as environment and diet (using data obtained from environment questionnaires and the results of both FFQ and Three day 24h diet recall)</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">2350</enrollment>
  <condition>Cardiometabolic Disease</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metabolic syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Severly obese patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Type-2 diabetics patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with first recent (&lt; 2 weeks) acute coronary syndrome (ACS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with stable chronic coronary artery disease without heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with ischemic systolic heart failure (CHF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with non-ischemic chronic heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adipose tissue biopsies (omental and subcutaneous) liver</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CT-scan</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stools sampling</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DNA sampling</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urine sampling</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dual energy X-ray absorptiometry-scan (DEXA-scan)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_label>Group 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1: metabolic syndrome (upon International Diabetes Federation (IDF) definition) -
        Wait circumference &gt; 94cm for men and &gt;80cm for women

        With at least 2 of the 4 following criteria:

          -  systolic blood pressure ≥ 130 mmHg and /or diastolic blood pressure ≥85 mmHg

          -  Triglyceride (TG) ≥1.50mg/dl (1.71mmol/l)

          -  HDL-c&lt;40mg/dl (1.03mmol/l) for men or HDL-c&lt;50mg/dl (1.29mmol/l) for women

          -  1g/l &lt;fasting glycemia &lt;1.26g/l without anti diabetic treatment

          -  or patients receiving anti hypertensive or anti cholesterol treatment (statin or
             fibrates).

        Group 2: obese

          -  BMI &gt;35 kg/m2

          -  Half going to bariatric surgery with or without type 2 diabetes

          -  Half no diabetic without surgery.

        Group 3: type 2 diabetes

          -  BMI&gt; 27 kg/m2,

          -  Patients treated with Biguanides and/or sulfonylurea and/ or DPPIV inhibitor and/ or
             analog and or insulin.

        Group 4:

          -  ACS without persistent ST elevation (ST-)

          -  Or ACS with persistent ST elevation (STEMI)

        Group 5:

          -  Stable CAD

          -  Left ventricular ejection fraction &gt; 50 %

        Group 6:

          -  CHF due to LV systolic dysfunction (LV ejection fraction &gt; 45 %)

          -  Past history of ACS and /or documented CAD

        Group 7:

          -  CHF due to LV systolic dysfunction (LV ejection fraction &lt; 45 %)

          -  No Past history of ACS and /or documented CAD

        Group 8:

        - Healthy volunteers

        Exclusion Criteria:

          -  &lt;18 or &gt;70 years old

          -  Past history of abdominal cancer+/- radiation therapy on the abdomen

          -  Patients with past history of abdominal surgery including intestinal resection of the
             gastrointestinal tract

          -  Participants with acute or chronic inflammatory or infectious diseases (including
             hepatitis C virus (HCV), hepatitis B virus (HBV) and Human immunodeficiency virus
             (HIV))

          -  Organ transplantation  and patients on Immunosuppressive therapy

          -  Patients with severe kidney failure and or patients on dialysis therapy (serum
             creatinine &gt; 150 µmol/l or Epidermal growth factor receptor (eGFR) &lt; 60 ml/min per
             1.73 m2 body surface area)

          -  Patients who are already included in a clinical study which implies testing any
             pharmaceutical drug. On the other hand, patients recruited in other observational
             studies can be recruited in METACARDIS

          -  Patients who do not understand the research procedures or those that are
             institutionalized, or those unable to give informed consent

          -  Patients who decline participation

          -  Patients with drug addiction

        Temporary exclusion criteria:

          -  Recent antibiotic treatment (&lt;2months)

          -  Patients on non-steroid anti-inflammatory treatment

          -  Patients on laxative therapy that could modify the bowel transit

          -  Pregnant women or breast feeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Clement, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karine Clement, Professor</last_name>
    <phone>0033(0) 1 4217 7928</phone>
    <email>karine.clement@psl.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oluf Borbye Pedersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karine Clement, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Stumvoll, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Coronary artery diseases</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Omics (ie transcriptomics, metabolomics, metagenomics, lipidomics)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
